Biopharma company Corcept Therapeutics (NASDAQ: CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect.
Corcept missed analysts’ revenue expectations last quarter, reporting revenues of $164.9 million, up 4.9% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates.
Is Corcept a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Corcept’s revenue to grow 8.4% year on year, slowing from the 18.7% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Corcept has missed Wall Street’s revenue estimates multiple times over the last two years.
With Corcept being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for pharmaceuticals stocks. However, investors in the segment have had steady hands going into earnings, with share prices up 1.9% on average over the last month. Corcept is up 1.8% during the same time .
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
